MarketCap
Kazia Therapeutics Limited KZIA
$ 7.7
-0.84%
Facebook
X
Telegram
Kazia Therapeutics Limited Revenue | KZIA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Kazia Therapeutics Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42 K | 2.31 M | - | - | - | - | - | 119 K | 249 K | 406 K | - | - | 1.07 M | 1.51 M | 2.02 M |
Annual performance
Select metrics to display
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.31 M | 42 K | 966 K |
Quarterly Revenue Kazia Therapeutics Limited
| 2026-Q2 | 2025-Q4 | 2025-Q2 | 2024-Q2 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 2.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in AUD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.31 M | 2.31 M | 2.31 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Fate Therapeutics
FATE
|
6.65 M | $ 2.06 | -2.37 % | $ 245 M |  USA |
 |
Eton Pharmaceuticals
ETON
|
80 M | $ 50.94 | 1.88 % | $ 1.37 B | USA |
 |
Fulcrum Therapeutics
FULC
|
80 M | $ 3.65 | -0.81 % | $ 231 M | USA |
 |
Hutchison China MediTech Limited
HCM
|
549 M | $ 14.3 | -0.42 % | $ 12.3 B |  China |
 |
IDEAYA Biosciences
IDYA
|
219 M | $ 33.05 | -4.78 % | $ 2.92 B | USA |
 |
InflaRx N.V.
IFRX
|
29.3 K | $ 1.59 | 1.6 % | $ 107 M |  Germany |
 |
Immutep Limited
IMMP
|
10.3 M | $ 3.07 | -4.22 % | $ 4.47 B |  Australia |
 |
Kala Pharmaceuticals
KALA
|
3.89 M | $ 0.18 | -3.52 % | $ 1.47 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
36.5 M | $ 0.28 | 0.25 % | $ 223 M |  Britain |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
678 M | $ 71.55 | -6.75 % | $ 5.31 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
146 M | $ 0.46 | -10.55 % | $ 5.03 K | USA |
 |
MediciNova
MNOV
|
410 K | $ 1.4 | 0.72 % | $ 68.7 M | USA |
 |
Seres Therapeutics
MCRB
|
789 K | $ 2.02 | -3.35 % | $ 17.9 M | USA |
 |
MediWound Ltd.
MDWD
|
21.8 M | $ 11.99 | -0.08 % | $ 326 M |  Israel |
 |
SELLAS Life Sciences Group
SLS
|
1 M | $ 11.55 | 0.1 % | $ 1.26 B | USA |
 |
Precigen
PGEN
|
9.68 M | $ 6.13 | -0.97 % | $ 1.92 B | USA |
 |
Avidity Biosciences
RNA
|
18.8 M | $ 8.03 | -2.07 % | $ 1.11 B | USA |
 |
Summit Therapeutics
SMMT
|
705 K | $ 14.61 | -5.59 % | $ 10.9 B | Britain |
 |
Celsion Corporation
CLSN
|
500 K | - | -6.63 % | $ 13.9 M | USA |
 |
I-Mab
IMAB
|
27.6 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Scholar Rock Holding Corporation
SRRK
|
33.2 M | $ 41.54 | 0.12 % | $ 4.76 B | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Abcam plc
ABCM
|
362 M | - | - | $ 4.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
8.28 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
12 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
5 K | - | - | $ 12.5 M |  Belgium |
 |
Galapagos NV
GLPG
|
1.11 B | - | - | $ 1.83 B | Belgium |
 |
Tiziana Life Sciences PLC
TLSA
|
-82 K | $ 0.88 | -7.37 % | $ 93.9 M | Britain |
 |
Teligent, Inc.
TLGT
|
45.3 M | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
11.7 M | - | - | $ 2.91 B | USA |
 |
Aphria Inc.
APHA
|
543 M | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
15 M | - | -0.90 % | $ 104 M | USA |
 |
Chiasma, Inc.
CHMA
|
1.11 M | - | -6.00 % | $ 238 M | USA |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
74.5 M | - | - | $ 376 M | USA |
 |
Cerecor Inc.
CERC
|
6.7 M | - | -1.68 % | $ 283 M | USA |
 |
Auris Medical Holding Ltd.
EARS
|
174 K | - | -1.77 % | $ 39.2 M |  Bermuda |